Skip to main content

EMD Biosciences to Market siRNA, DNA Transfection Reagents from DNT

NEW YORK (GenomeWeb News) – EMD Biosciences, part of Merck KGaA’s Performance and Life Science Chemicals division, has signed an exclusive license and supply agreement with Dendritic Nanotechnologies for siRNA and DNA transfection reagents, the companies said today.
 
Under the terms of the agreement, DNT a US subsidiary of Australian firm Starpharma, will supply EMD Biosciences with its Priofect transfection reagents. EMD will market the reagents through its Novagen product line.
 
DNT retains full rights to all in vivo aspects of transfecting nucleic acids with the Priostar technology. Additional terms of the agreement, which includes royalties and milestone payments, were not disclosed.
 
According to DNT, PrioFect transfection reagents offer nanometer-size control, which will enable EMD to offer siRNA transfection reagents with sizes optimized for individual cell lines.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.